Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel
Red mite vaccine research receives funding
Grant awarded for development of vaccine

The Biotechnology and Biological Sciences Research Council (BBSRC) has awarded funding of £550,000 to the Moredun Research Institute in Scotland, in collaboration with Pfizer Animal Health.

The research grant has been awarded to boost research into the development of a vaccine to protect hens against red mites.

Red mite attacks on hens can cause serious health problems, leading to anaemia, feather-pecking and an increased incidence of cannabilism. Dr Alisdair Nisbet, who is heading the project at Moredun speaks of the growing problems posed by red mites:

"Controlling mite populations is now a major problem, with most pesticides affording only limited or short-lived reduction in the population of mites.

"There is also the issue of development of drug resistance and environmental contamination, which means there is an urgent need to develop alternative control strategies."

The research aims to determine whether laying hens can be vaccinated using specific extracts of the mites, to induce an immune response that will kill the mites when they take a blood meal. Trials have been ongoing at Moredun since 2006, achieving approximately 75% death rate amongst red mites coming into contact with the prototype vaccine, according to Nisbet.

"[This] has been a real positive," says Nisbet "but clearly cultivating red mites for extracts is not appealing, so this new project with Pfizer and BBSRC is designed to be more commercially oriented.

"Our goal is to identify the bits of the mite that will induce the best immune responses in the hens and produce large quantities of these, using recombinant technologies to enable large-scale vaccination trials to take place."

Funding is in place for the next three years, and it is hoped that a new prototype vaccine will be available by the end of this period, which could then be made commercially.

Become a member or log in to add this story to your CPD history

Birmingham Dogs Home makes urgent appeal

News Story 1
 Birmingham Dogs Home has issued an urgent winter appeal as it faces more challenges over the Christmas period.

The rescue centre has seen a dramatic increase in dogs coming into its care, and is currently caring for over 200 dogs. With rising costs and dropping temperatures, the charity is calling for urgent support.

It costs the charity £6,000 per day to continue its work.

Fi Harrison, head of fundraising and communications, said: "It's heart-breaking for our team to see the conditions some dogs arrive in. We really are their last chance and hope of survival."

More information about the appeal can be found here

Click here for more...
News Shorts
Avian flu confirmed at premises in Cornwall

A case of highly pathogenic avian influenza H5N1 has been detected in commercial poultry at a premises near Rosudgeon, Cornwall.

All poultry on the infected site will be humanely culled, and a 3km protection zone and 10km surveillance zone have been put in place. Poultry and other captive birds in the 3km protection zone must be housed.

The case is the second avian flu case confirmed in commercial poultry this month. The H5N5 strain was detected in a premises near Hornsea, East Riding of Yorkshire, in early November. Before then, the disease had not been confirmed in captive birds in England since February.

The UK chief veterinary officer has urged bird keepers to remain alert and practise robust biosecurity.

A map of the disease control zones can be found here.